JD-SW
09618
XIAOMI-W
01810
BEKE-W
02423
ALI HEALTH
00241
BABA-W
09988
HK Stock MarketDetailed Quotes
02197 CLOVER BIO-B
- 0.229
- +0.005+2.23%
Not Open Jan 17 16:08 CST
297.03MMarket Cap-0.31P/E (TTM)
0.233High0.223Low819.05KVolume0.224Open0.224Pre Close186.77KTurnover0.06%Turnover RatioLossP/E (Static)1.30BShares0.58052wk High-0.33P/B297.03MFloat Cap0.20152wk Low--Dividend TTM1.30BShs Float14.800Historical High--Dividend LFY4.46%Amplitude0.201Historical Low0.228Avg Price500Lot Size--Div YieldTTM--Div Yield LFY
CLOVER BIO-B News
Express News | Clover Announces Positive Clinical Data for Rsv Vaccine Candidate Scb-1019 Compared Head-to-Head Versus GSK's Arexvy
Clover Biopharmaceuticals Swings to Loss in H1
Express News | Clover Biopharmaceuticals H1 Net Income RMB -95.1 Million
Express News | Clover Biopharmaceuticals Ltd: Full Phase Ⅰ Data Readout Is Planned by Year-End 2024
Express News | Clover Biopharmaceuticals: Bivalent Scb-1019 Significantly Boosted Rsv-a and Rsv-B Neutralizing Antibody Titers in Older Adults
Express News | Clover Biopharmaceuticals Ltd: Study Showed Favorable Safety & Reactogenicity Profile Comparable to Saline Placebo
Express News | Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent Rsv Vaccine Candidate Scb-1019 in Older Adults
Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial
Clover Biopharmaceuticals Trims Losses in 2023
Clover Biopharmaceuticals Publishes Positive Results From SCB-219M Clinical Trial
Clover Biopharmaceuticals Completes Patient Enrollment for Australia Phase 1 Trial; Shares Fall 5%
Clover Biopharmaceuticals Rolls Out Quadrivalent Seasonal Influenza Vaccine in Mainland China
CEO & Executive Director of Clover Biopharmaceuticals Picks Up 2.7% More Stock
Clover Biopharmaceuticals CEO Boosts Shareholding
While Institutions Invested in Clover Biopharmaceuticals, Ltd. (HKG:2197) Benefited From Last Week's 53% Gain, Individual Investors Stood to Gain the Most
Clover Biopharmaceuticals Expects Swing to Profit in H1
Express News | Clover Biopharmaceuticals Results Mainly Supported by Other Income
Clover Biopharmaceuticals: 1H Net Profit Likely at Least CNY500.0M Vs. CNY1.14B Loss a Year Earlier
Clover Biopharmaceuticals' First-Half Expenses Fall 50%; Shares Jump 7%
Clover Biopharmaceuticals' 2022 Loss Narrows; Shares Tumble 9%
Trending HK Stocks
HK Tech and Internet Stocks HK Tech and Internet Stocks
Stocks of companies primarily involved in technology and internet sectors in the HK stock market.Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Tech and Internet Stocks, ranked from highest to lowest based on real-time market data. Stocks of companies primarily involved in technology and internet sectors in the HK stock market.Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Tech and Internet Stocks, ranked from highest to lowest based on real-time market data.
